- 1 Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and 2 infection rebound: a retrospective cohort study
- 3

4 Supplementary methods

5 6 **Logistic regression models**

- 7 <u>Model fitting.</u>
- 8 We fitted Bayesian logistic regression models for the probability of an individual having Ct value 9 <30 on each day post detection using the *brms* package version 2.14.4. Models were run on the 10 Harvard FAS Research Computing cluster using R version 4.0.2. For each model, we ran 4 chains 11 for 2000 iterations each. Weakly informative priors (normal distributions with means of 0 and 12 standard deviations of 10) were used for all model parameters. We assessed convergence based
- 13 on all estimated parameters having a Gelman R-hat statistic less than 1.1.
- 14

15 Viral kinetics model

16 Statistical analysis.

- Following previously described methods,^{1,2} we used a Bayesian hierarchical model to estimate 17 18 the proliferation duration, clearance duration, and peak viral concentration for acute SARS-CoV-19 2 infections, stratified by variant (Omicron, Delta, Other), immune status (vaccination history, 20 including unexposed, 1-2 doses, or boosted; and antibody titer, including unexposed, titer ≤ 250 21 AU, and titer > 250 AU) and age (groups of <30, 30-50, and >50 years old). The model describes 22 the log₁₀ viral concentration during an acute infection using a continuous piecewise-linear curve 23 with control points that specify the time of acute infection onset, the time and magnitude of peak 24 viral concentration, and the time of acute infection clearance. The assumption of piecewise 25 linearity is equivalent to assuming exponential viral growth during the proliferation period followed 26 by exponential viral decay during the clearance period. The control points were inferred using the Hamiltonian Monte Carlo algorithm as implemented in Stan (version 2.24).³ We used priors 27 informed by a previous analyses.^{1,2} Data and code are available online. 28
- 29 30 Model fitting.

To restrict to a set of well-observed acute infections for model fitting, we first removed any sequences of 3 or more consecutive negative tests (Ct = 40) from each acute infection to avoid overfitting to these trivial values. We kept only acute infections with at least one Ct value < 32 and at least 3 Ct values < 40 (the limit of detection).

35

We constructed a piecewise-linear regression model to estimate the peak Ct value, the time from infection onset to peak (*i.e.* the duration of the proliferation stage), and the time from peak to infection resolution (*i.e.* the duration of the clearance stage). This is represented by the equation

39 40

$$E[Ct(t)] = \begin{cases} 1.\text{o.d} - \frac{\delta}{t_p - t_o}(t - t_o) & t \le t_p \\ 1.\text{o.d} - \delta + \frac{\delta}{t_r - t_p}(t - t_p) & t > t_p \end{cases}$$

Here, E[Ct(t)] represents the expected value of the Ct at time *t*, "I.o.d" represents the RT-qPCR limit of detection, δ is the absolute difference in Ct between the limit of detection and the peak (lowest) Ct, and *t*_o, *t*_p, and *t*_r are the onset, peak, and recovery times, respectively.

44

45 Before fitting, we re-parametrized the model using the following definitions:46

• $\Delta Ct(t) = 1.o.d. - Ct(t)$ is the difference between the limit of detection and the observed Ct value at time *t*.

49 • $\omega_p = t_p - t_o$ is the duration of the proliferation stage.

• $\omega_r = t_r - t_p$ is the duration of the clearance stage.

52 We next characterized the likelihood of observing a given $\Delta Ct(t)$ using the following mixture 53 model:

$$\sum_{k=1}^{55} L(\Delta Ct(t) = x|\delta, t_p, \omega_p, \omega_r) = (1-\lambda) \Big[f_N(x|E[\Delta Ct(t)], \sigma(t)) + I_{lod}F_N(0|E[\Delta Ct(t)], \sigma(t)) \Big] + \lambda f_{\text{Exp}}(x|\kappa) \Big]$$

57 The left-hand side of the equation denotes the likelihood (L) that the observed viral load, as 58 measured by Ct deviation from the limit of detection ($\Delta Ct(t)$), is equal to some quantity x given the 59 model parameters δ (peak viral load), t_{ρ} (time of peak viral load), ω_{ρ} (proliferation time), and ω_{r} 60 (clearance time). This likelihood is equal to the sum of two main components: the likelihood that 61 the observed value was generated by the modeled viral kinetic process, denoted by the bracketed 62 term preceded by a $(1-\lambda)$; and the likelihood that the observed value was a false negative, denoted 63 by the term preceded by a λ . In the bracketed term representing the modeled viral kinetic process. 64 $f_N(x \mid E[\Delta Ct(t)], \sigma(t))$ represents the Normal PDF evaluated at x with mean $E[\Delta Ct(t)]$ (generated by 65 the model equations above) and observation noise $\sigma(t)$. $F_N(0 \mid E[\Delta Ct(t)], \sigma(t))$ is the Normal CDF 66 evaluated at 0 with the same mean and standard deviation. This represents the scenario where 67 the true viral load goes below the limit of detection, so that the observation sits at the limit of 68 detection. I_{lod} is an indicator function that is 1 if $\Delta Ct(t) = 0$ and 0 otherwise; this way, the F_N term 69 acts as a point mass concentrated at $\Delta Ct(t) = 0$. Last, $f_{Exp}(x \mid \kappa)$ is the Exponential PDF evaluated 70 at x with rate κ . We set $\kappa = \log(10)$ so that 90% of the mass of the distribution sat below 1 Ct unit 71 and 99% of the distribution sat below 2 Ct units, ensuring that the distribution captures values 72 distributed at or near the limit of detection. We did not estimate values for λ or the exponential 73 rate because they were not of interest in this study; we simply needed to include them to account for some small probability mass that persisted near the limit of detection to allow for the possibility 74 75 of false negatives. A schematic of the likelihood function is depicted in Supplementary Figure 76 17. 77

78 We used a hierarchical structure with a non-centered parameterization to describe the 79 distributions of ω_p , ω_r , and δ for each person:

80

50

51

54

 $\omega_{\rm p}[i] = \mathrm{Exp}[\mu_{\omega \rm p} + \zeta^{i}_{\rm wp} + \sigma_{\rm wp} N^{i}_{\rm wp}] \,\omega^{*}_{\rm p}$ 81

82
$$\omega_r[i] = \text{Exp}[\mu_{\omega r} + \zeta_{wr}^i + \sigma_{wr} N_{wr}^i] \omega_r^*$$

83
$$\delta[i] = \operatorname{Exp}[\mu_{\delta} + \zeta_{\delta}^{i} + \sigma_{\delta} N_{\delta}^{i}] \delta^{*}$$

84

Here, ω_{p}^{*} , ω_{r}^{*} , and δ^{*} are user-defined estimated values for the means of ω_{p} , ω_{r} , and δ , so that 85 86 the exponential terms represent an adjustment factor relative to that midpoint defined by μ (a shared adjustment factor for the entire population), ζ^{i} (an adjustment factor shared among 87 individuals of a given variant/immune category), and σ (a shared standard deviation for the entire 88 89 population). The N¹ terms represent individual-level random effects. The prior distributions for the 90 μ , ζ , and σ terms were all Normal(0, 0.25) (with σ truncated to have support on the positive reals). 91 These prior distributions define LogNormal adjustment factors that have ~99% of their probability 92 mass between 0.5 and 2, so that the prior distributions for $\omega_{\rm p}$, $\omega_{\rm r}$, and δ cover roughly half to twice 93 their prior estimated midpoint values.

94

We used a Hamiltonian Monte Carlo fitting procedure implemented in Stan (version 2.24) and R (version 3.6.2) to estimate the parameters. We ran four MCMC chains for 2,000 iterations each with a target average proposal acceptance probability of 0.8. The first half of each chain was discarded as the warm-up. The Gelman R-hat statistic was less than 1.1 for all parameters. This 99 indicated good overall mixing of the chains. There were no divergent iterations, indicating good100 exploration of the parameter space.

101 **References**

- 102 1. Kissler, S. M. *et al.* Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. *PLoS Biol.* **19**, e3001333 (2021).
- 104 2. Kissler, S. M. et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and
- 105 Unvaccinated Persons. *N. Engl. J. Med.* **385**, 2489–2491 (2021).
- 106 3. Carpenter, B. *et al.* Stan: A Probabilistic Programming Language. *J. Stat. Softw.* **76**, 1–32 (2017).
- 108



- 111 Figure S1. Summary of cohort. Top row describes cohort demographics and data on immune
- histories. Middle row describes infection data. Bottom row provides additional information on the
- infection data.



Figure S2. Distribution of delays from detection to symptom onset among individuals with

known symptom status. Dashed lines mark the median delay between detection and symptomonset. Solid lines mark the day of detection (0).



120 121 **Figure S3.** Distribution of delays from symptom onset to peak Ct values among individuals with

- 122 known symptom status. Dashed lines mark the median delay between detection and symptom
- 123 onset. Solid lines mark the day of symptom onset (0).





Figure S4. (A) Frequency of sequenced and unsequenced detected infections over time by 126 week. Vertical dashed lines and shaded backgrounds demarcate periods of variant dominance.

127 (B) Proportion of sequenced infections attributable to Delta, Omicron or other lineages. 128 **Table S1.** Number of identified rebounds stratified by variant, either confirmed through

sequencing or assumed based on detection date. Rebounds are defined here as any trajectory

130 with an initial Ct value <30, followed by a sequence of two or more consecutive negative tests or

131 tests with Ct value \geq 30, and subsequently followed by two or more consecutive tests with Ct 132 value < 30.

132 v 133

Lineage	Rebounds	Total infections	Percentage rebounded
Omicron	36	877	4.10%
Delta	1	178	0.562%
Other	3	279	1.08%

134 135

136 **Table S2.** Number of identified rebounds stratified by vaccination status. Rebounds are defined

here as any trajectory with an initial Ct value <30, followed by a sequence of two or more

138 consecutive negative tests or tests with Ct value \geq 30, and subsequently followed by two or more 139 consecutive tests with Ct value <30.

140

Vaccination status	Rebounds	Total infections	Percentage rebounded
Boosted	32	494	6.48%
No record	5	398	1.26%
Second dose	3	323	0.929%
Unvaccinated	2	159	1.26%



143 Supplementary Figure S5. All viral trajectories classified as rebound shown in Figure 1B.

144 Subplots are colored by the most stringent definition for rebound. To be included here,

- 145 individuals must have 2+ consecutive days of Ct≥30 after an initial Ct<30. The vertical red
- 146 dotted line marks this initial clearance time. Trajectories are then classified as rebounds

- following either two consecutive tests with Ct<30 (purple), two consecutive tests with Ct<30 but
- 148 with at least a 2 Ct decrease (green), or two consecutive tests with Ct<25 (yellow). The vertical
- 149 red line marks the timing of rebound detection. The horizontal dashed lines show the different Ct
- 150 value thresholds for rebound classification. Panels are labeled by arbitrary person ID and
- 151 infection number.

152 **Table S3.** Comparison of linear logistic regression models predicting probability of Ct<30 on

each day since detection among individuals in the frequent testing group. Models are ranked

based on their expected log pointwise predictive density (ELPD), where a lower ELPD implies

better prediction accuracy. Model weight refers to the weight of each model in a Bayesian Model
 Averaging analysis, where a higher value implies a greater contribution to model prediction

157 when combining multiple models. AUC = area under the curve.

158

Model	ELPD difference	SE difference	Model weight	AUC	Classification accuracy	Accuracy (>=30)	Accuracy (<30)
Cumulative number of exposures and lineage	0.000	0.000	0.189	0.900	0.828	0.894	0.637
Days since previous exposure and lineage	-6.053	11.613	0.281	0.899	0.826	0.892	0.634
Vaccination status and lineage	-6.907	11.836	0.292	0.899	0.826	0.887	0.649
Cumulative number of exposures	-24.622	8.645	0.237	0.895	0.824	0.898	0.609
Vaccination status	-43.428	13.353	0.000	0.892	0.821	0.888	0.626
Days since previous exposure	-44.910	13.731	0.001	0.893	0.821	0.890	0.619
Lineage	-74.343	12.956	0.000	0.889	0.819	0.892	0.607
Baseline	-80.956	14.080	0.000	0.887	0.819	0.895	0.597

161 **Table S4.** Comparison of linear logistic regression models predicting probability of Ct<30 on

162 each day since detection among individuals in the delayed testing group. Models are ranked

163 based on their expected log pointwise predictive density (ELPD), where a lower ELPD implies

better prediction accuracy. Model weight refers to the weight of each model in a Bayesian Model
 Averaging analysis, where a higher value implies a greater contribution to model prediction

166 when combining multiple models. AUC = area under the curve.

167

Model	ELPD difference	SE difference	Model weight	AUC	Classification accuracy	Accuracy (>=30)	Accuracy (<30)
Cumulative number of exposures and lineage	0.000	0.000	0.314	0.912	0.848	0.895	0.696
Cumulative number of exposures	-3.543	6.862	0.282	0.911	0.847	0.895	0.695
Vaccination status and lineage	-19.169	12.714	0.404	0.911	0.846	0.890	0.705
Vaccination status	-31.913	13.496	0.000	0.909	0.846	0.890	0.704
Days since previous exposure and lineage	-44.479	12.735	0.000	0.910	0.846	0.891	0.705
Lineage	-61.323	13.566	0.000	0.908	0.844	0.883	0.719
Days since previous exposure	-87.874	15.524	0.000	0.906	0.844	0.882	0.721
Baseline	-117.764	17.502	0.000	0.904	0.840	0.877	0.724



170 171

Figure S6. Proportion of infections with Ct value <30 on each day post detection by confirmed 172 or suspected variant, vaccination status and detection group. Solid colored lines and shaded

173 ribbons are posterior estimates from a generalized linear model predicting probability of Ct value

- 174 <30 as a function of days since detection and vaccination status, showing the posterior mean
- 175 (solid line) and 95% credible intervals (shaded ribbon) of each conditional effect. Dotted
- 176 horizontal and vertical lines show 5% probability and day 5 post detection respectively.



178 179 Figure S7. Identical to Supplementary Figure 6, but after excluding data from all players.



180 181 Figure S8. Proportion of Omicron infections, stratified by symptom status, with Ct value <30 on 182 each day post detection by booster status and detection group. Solid colored lines and shaded 183 ribbons are posterior estimates from a generalized linear model predicting probability of Ct value 184 <30 as a function of days since detection and vaccination status, showing the posterior mean 185 (solid line) and 95% credible intervals (shaded ribbon) of each conditional effect. 186



188 Figure S9. Proportion of BA.1-infected individuals with Ct value <30 on each day post detection 189 stratified by detection group and either (A) age group after conditioning on vaccination status 190 and lineage (conditioned on BA.1 infection and boosted status) or (B) vaccination status after 191 conditioning on age group (conditioned on BA.1 infection and age group <30 years). Posterior estimates are from a generalized linear model predicting probability of Ct value <30 with spline 192 193 terms for the interaction between days since detection with age group and the interaction 194 between days since detection with vaccination status and variant. Solid colored lines and shaded ribbons show the posterior mean (solid line) and 95% credible intervals (shaded ribbon) 195 196 of each conditional effect.







Previous exposure type • Infection • Vaccination

Figure S10. (**A**) Measured antibody titers by date of sample collection. Lines show longitudinal samples from the same individual, colored by the most recent exposure at the time of sample

200 collection. Lines going up therefore represent antibody boosting events, and lines going down

represent waning. (**B**) Measured antibody titers by days since previous exposure at time of

202 sample collection.



- 205 **Figure S11.** (A) Distribution of vaccination dates (note that most first doses were administered
- prior to 2021-06-25). (B) Distribution of serum sample times. (C) Heatmap of individual
- 207 exposure status over time. Rows represent individuals and columns represent date. Each cell is
- 208 shaded by the number of prior exposures at that date. Points show detected infections,
- 209 recorded vaccinations, and serum samples.



Figure S12. Histogram of time between (A) second vaccine dose and antibody titer

- measurement and (B) booster dose and antibody titer measurement. Dashed line marks
 the median lag (162 days). 1 individual was infected between receiving their second vaccine
- 215 dose and having a titer measurement taken (Delta infection). 42 individuals were infected
- between having their titer measurement taken and receiving their booster vaccine dose (32
- 217 Delta; 9 unsequenced; 1 confirmed Omicron BA.1).
- 218



219 220

Figure S13. Proportion of infections with Ct value <30 on each day post detection stratified by single point-in-time anti-spike antibody titer against ancestral SARS-CoV-2 measured by the

222 Diasorin Trimeric Assay. Solid colored lines and shaded ribbons are posterior estimates from a

223 generalized linear model predicting probability of Ct value <30 as a function of days since

detection and titer/vaccination status category, showing the posterior mean (solid line) and 95% aredible intervals (shaded ribbon) of each conditional effect

credible intervals (shaded ribbon) of each conditional effect.



226 227

Figure S14. Identical to Omicron plots shown in Supplementary Figure 11, but only including individuals who had antibody titers measured between 100 and 200 days following a known

previous infection of vaccination (A) or including infections between 60 and 90 days after an

- antibody titer measurement (B).
- 231



232 233 Figure S15. (A) Distribution of antibody titers among Omicron BA.1-infected individuals (colored 234 points) stratified by age group and vaccination status, with mean titers (large black points) and 235 bootstrapped 95% confidence intervals for the mean (horizontal lines). Note that stratification is 236 by infection and not individual, and that antibody titers were measured at a single point in time rather than near the time of infection. The Diasorin Trimeric Assay values are truncated be-237 tween 13 and 800 AU/ml. (B) Proportion of BA.1-infected individuals with Ct value <30 on each 238 239 day post detection stratified by detection group after conditioning on age group. Posterior 240 estimates are from a generalized linear model predicting probability of Ct value <30 with spline terms for the interaction between days since detection with age group and the interaction 241 242 between days since detection with vaccination status and antibody titer group. Solid colored 243 lines and shaded ribbons show the posterior mean (solid line) and 95% credible intervals 244 (shaded ribbon) of each conditional effect.

- 245
- 246

Table S5. Posterior estimates of viral trajectory attributes by variant and vaccinationstatus. Estimates are posterior means with 95% credible intervals. 248 249

Trajectory value	Variant/vaccination status	Estimate
Peak viral load (Ct)	Other: Unvaccinated	25.0 (24.2, 25.9)
	Delta: 1-2 doses	22.4 (21.4, 23.5)
	Omicron: 1-2 doses	25.6 (25.0, 26.2)
	Omicron: Boosted	25.7 (25.4, 26.1)
Peak viral load (log ₁₀ copies/ml)	Other: Unvaccinated	6.8 (6.6, 7.0)
	Delta: 1-2 doses	7.5 (7.2, 7.8)
	Omicron: 1-2 doses	6.6 (6.5, 6.8)
	Omicron: Boosted	6.6 (6.5, 6.7)
Proliferation time (days)	Other: Unvaccinated	3.5 (3.1, 3.9)
	Delta: 1-2 doses	3.6 (3.1, 4.1)
	Omicron: 1-2 doses	3.6 (3.3, 4.0)
	Omicron: Boosted	4.0 (3.8, 4.3)
Clearance time (days)	Other: Unvaccinated	9.9 (9.2, 10.6)
	Delta: 1-2 doses	7.6 (7.0, 8.3)
	Omicron: 1-2 doses	6.2 (5.8, 6.6)
	Omicron: Boosted	8.4 (8.0, 8.7)

254 255 Table S6. Posterior estimates of viral trajectory attributes by variant and antibody titer.Estimates are posterior means with 95% credible intervals.

Trajectory attribute	Variant/immune status	Estimate
Peak viral load (Ct)	Other: Unexposed	24.8 (24.0, 25.6)
	Delta: Exposed, ≤250 AU	22.1 (20.6, 23.4)
	Delta: Exposed, >250 AU	24.4 (22.7, 26.1)
	Omicron: Exposed, ≤250 AU	25.2 (24.7, 25.6)
	Omicron: Exposed, >250 AU	26.2 (25.7, 26.6)
Peak viral load (log ₁₀	Other: Unexposed	
copies/mi)		6.9 (6.6, 7.1)
	Delta: Exposed, ≤250 AU	7.6 (7.3, 8.0)
	Delta: Exposed, >250 AU	7.0 (6.5, 7.4)
	Omicron: Exposed, ≤250 AU	6.8 (6.7, 6.9)
	Omicron: Exposed, >250 AU	6.5 (6.4, 6.6)
Proliferation time (days)	Other: Unexposed	3.5 (3.2, 3.9)
	Delta: Exposed, ≤250 AU	3.6 (2.8, 4.5)
	Delta: Exposed, >250 AU	4.2 (3.3, 5.3)
	Omicron: Exposed, ≤250 AU	3.9 (3.6, 4.2)
	Omicron: Exposed, >250 AU	3.7 (3.5, 4.0)
Clearance time (days)	Other: Unexposed	9.8 (9.1, 10.6)
	Delta: Exposed, ≤250 AU	7.7 (6.9, 8.7)
	Delta: Exposed, >250 AU	7.6 (6.4, 8.8)
	Omicron: Exposed, ≤250 AU	8.4 (8.0, 8.8)
	Omicron: Exposed, >250 AU	6.9 (6.6, 7.3)

Table S7. Posterior estimates of Omicron BA.1 viral trajectory attributes by symptom andvaccination status. Estimates are posterior means with 95% credible intervals.

260

Trajectory attribute	Variant/immune status	Estimate
Peak viral load (Ct)	Omicron: 1-2 doses, no symptoms	26.7 (25.7, 27.7)
	Omicron: 1-2 doses, symptoms	25.3 (24.5, 26.1)
	Omicron: boosted, no symptoms	26.3 (25.7, 27)
	Omicron: boosted, symptoms	25.4 (25, 25.8)
Peak viral load (log ₁₀ copies/ml)	Omicron: 1-2 doses, no symptoms	6.3 (6.1, 6.6)
	Omicron: 1-2 doses, symptoms	6.7 (6.5, 6.9)
	Omicron: boosted, no symptoms	6.4 (6.3, 6.6)
	Omicron: boosted, symptoms	6.7 (6.6, 6.8)
Proliferation time (days)	Omicron: 1-2 doses, no symptoms	3.7 (3.2, 4.2)
	Omicron: 1-2 doses, symptoms	3.7 (3.2, 4.2)
	Omicron: boosted, no symptoms	4.3 (3.9, 4.8)
	Omicron: boosted, symptoms	3.8 (3.5, 4.1)
Clearance time (days)	Omicron: 1-2 doses, no symptoms	5.9 (5.2, 6.6)
	Omicron: 1-2 doses, symptoms	6.3 (5.8, 6.8)
	Omicron: boosted, no symptoms	7.4 (6.8, 8.0)
	Omicron: boosted, symptoms	8.7 (8.3, 9.1)

263 264 Table S8. Posterior estimates of Omicron BA.1 viral trajectory attributes by symptom andantibody titer. Estimates are posterior means with 95% credible intervals.

Trajectory attribute	Variant/immune status	Estimate
Peak viral load (Ct)	Omicron: Low titer, no symptoms	26.1 (25.2, 26.9)
	Omicron: Low titer, symptoms	24.8 (24.3, 25.4)
	Omicron: High titer, no symptoms	26.7 (25.9, 27.5)
	Omicron: High titer, symptoms	25.9 (25.4, 26.5)
Peak viral load (log ₁₀ copies/ml)	Omicron: Low titer, no symptoms	6.5 (6.3, 6.8)
	Omicron: Low titer, symptoms	6.9 (6.7, 7.0)
	Omicron: High titer, no symptoms	6.3 (6.1, 6.6)
	Omicron: High titer, symptoms	6.6 (6.4, 6.7)
Proliferation time (days)	Omicron: Low titer, no symptoms	4.3 (3.8, 4.9)
	Omicron: Low titer, symptoms	3.6 (3.3, 4.0)
	Omicron: High titer, no symptoms	3.8 (3.4, 4.3)
	Omicron: High titer, symptoms	3.8 (3.4, 4.2)
Clearance time (days)	Omicron: Low titer, no symptoms	7.4 (6.7, 8.1)
	Omicron: Low titer, symptoms	8.7 (8.2, 9.3)
	Omicron: High titer, no symptoms	6.4 (5.8, 7.1)
	Omicron: High titer, symptoms	7.1 (6.6, 7.5)

Table S9. Posterior estimates of Omicron BA.1 viral RNA clearance times by age and
 vaccination status. Estimates are posterior means with 95% credible intervals. Low titer is
 ≤250 AU, high titer is >250 AU.

Trajectory attribute	Variant/immune status	Estimate
Peak viral load (Ct)	Omicron: <30, unboosted	25.6 (25, 26.3)
	Omicron: <30, boosted	25.8 (25.1, 26.4)
	Omicron: 30-50, unboosted	25.3 (24.2, 26.5)
	Omicron: 30-50, boosted	25.7 (25.2, 26.2)
	Omicron: 50+, unboosted	25.5 (22.8, 27.9)
	Omicron: 50+, boosted	25.5 (24.6, 26.3)
Peak viral load (log ₁₀ copies/ml)	Omicron: <30, unboosted	6.6 (6.4, 6.8)
	Omicron: <30, boosted	6.6 (6.4, 6.8)
	Omicron: 30-50, unboosted	6.7 (6.4, 7)
	Omicron: 30-50, boosted	6.6 (6.5, 6.7)
	Omicron: 50+, unboosted	6.7 (6, 7.4)
	Omicron: 50+, boosted	6.7 (6.5, 6.9)
Proliferation time (days)	Omicron: <30, unboosted	3.7 (3.4, 4.1)
	Omicron: <30, boosted	4.2 (3.8, 4.7)
	Omicron: 30-50, unboosted	3.6 (3, 4.4)
	Omicron: 30-50, boosted	4 (3.6, 4.3)
	Omicron: 50+, unboosted	4.4 (3, 6.3)
	Omicron: 50+, boosted	3.9 (3.4, 4.4)
Clearance time (days)	Omicron: <30, unboosted	6 (5.6, 6.5)
	Omicron: <30, boosted	7.2 (6.7, 7.7)
	Omicron: 30-50, unboosted	6.4 (5.7, 7.2)
	Omicron: 30-50, boosted	8.6 (8.1, 9.1)
	Omicron: 50+, unboosted	8.7 (6.6, 11.2)
	Omicron: 50+, boosted	9.6 (8.8, 10.6)

Table S10. Posterior estimates of Omicron BA.1 viral RNA clearance times by age andtiter. Estimates are posterior means with 95% credible intervals. Low titer is ≤250 AU, high titer is >250 AU.

Trajectory attribute	Variant/immune status	Estimate
Peak viral load (Ct)	Omicron: <30, low titer	24.8 (24, 25.5)
	Omicron: <30, high titer	26.2 (25.6, 26.8)
	Omicron: 30-50, low titer	25.4 (24.8, 26)
	Omicron: 30-50, high titer	26.1 (25.4, 26.8)
	Omicron: 50+, low titer	24.9 (23.8, 25.9)
	Omicron: 50+, high titer	26.3 (24.8, 27.6)
Peak viral load (log ₁₀	Omicron: <30 low titer	69(6771)
	Omicron: <30 high titer	65(63,67)
	Omicron: 30-50 low titer	67 (65 69)
	Omicron: 30-50, low liter	0.7 (0.3, 0.3)
	Omicron: 30-50, nigh liter	0.0 (0.3, 0.7)
	Omicron: 50+, low titer	6.8 (6.6, 7.1)
	Omicron: 50+, high titer	6.5 (6.1, 6.9)
Proliferation time (days)	Omicron: <30, low titer	3.9 (3.4, 4.3)
	Omicron: <30, high titer	4 (3.6, 4.4)
	Omicron: 30-50, low titer	4 (3.6, 4.4)
	Omicron: 30-50, high titer	3.6 (3.2, 4)
	Omicron: 50+, low titer	3.8 (3.2, 4.5)
	Omicron: 50+, high titer	3.7 (2.9, 4.7)
Clearance time (days)	Omicron: <30, low titer	7.2 (6.7, 7.8)
	Omicron: <30, high titer	6.2 (5.8, 6.7)
	Omicron: 30-50, low titer	8.7 (8.1, 9.3)
	Omicron: 30-50, high titer	7.4 (6.8, 8)
	Omicron: 50+, low titer	9.9 (8.7, 11.1)
	Omicron: 50+, high titer	9.5 (8, 11.1)





279 **Figure S16.** Correlation between authentic virus neutralization assay (ID50) and the Diasorin antibody titer against (A) wildtype and (B) Delta. Horizontal yellow bar shows an ID50 titer of 50 and 100 respectively, Diagonal lines and shaded regions show mean and 95% confidence intervals (CI) for a linear regression between the Diason antibody titer and ID50 titer. Vertical

- 284 line and shaded regions show point estimate and 95% CI for the Diasorin antibody titer corresponding to an ID50 titer of 50 (red) and 100 (green).



limit of detection (blue hatched region) is instead added to a point probability mass at the origin since viral loads below the limit of detection register at the limit of detection. The false negative distribution (II) is an exponential distribution with fixed rate to account for a small amount of noise near the limit of detection. Summing the process likelihood (I) and the false negative

likelihood (I) using the mixing probability λ (= 1 - sensitivity) yields the overall likelihood (III).

- 299
- 300